Completed PHASE1 INTERVENTIONAL NCT00557661

Safety Study of CD-NP in Heart Failure

A Multi-Center, Ascending Dose Trial to Assess the Safety, Pharmacokinetics and Pharmacodynamics of CD-NP Infusions in Patients With Congestive Heart Failure

Sponsor: Nile Therapeutics

Conditions Congestive Heart Failure

Interventions CD-NP

Updated 5 times since 2017 Last updated: Mar 23, 2009 Started: Nov 30, 2007 Completion: Dec 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Congestive Heart Failure and is currently completed. Nile Therapeutics leads this study, which shows 5 recorded versions since 2007 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Nov 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Nile Therapeutics

Data source: Nile Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.